Juno Therapeutics (JUNO) Misses Q2 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. KTOS
4. PLTR
5. SPY
6. AON
7. TMUS
8. LBRX
9. BMY
10. MRK

Go back to Juno Therapeutics (JUNO) Misses Q2 EPS by 23c

Juno Therapeutics Reports Second Quarter 2016 Financial Results

August 4, 2016 4:09 PM EDT

- Strong cash position of $1.11 billion -

- JCAR015 Phase II ROCKET trial resumes enrollment -

- JCAR015 U.S. approval projected as early as the first half of 2018 -

- Preliminary JCAR017 Phase I NHL data show encouraging efficacy and toxicity profile -

- Eight product candidates in clinical trials against six different targets -

- Juno reaffirms cash burn guidance -

- Conference call today at 5:00 p.m. Eastern Time -

... More